Introduction
Duchenne muscular dystrophy (DMD) is the most commonly diagnosed fatal childhood disorder, affecting approximately one in 3500 live male births. Although recent advances in palliative care have resulted in prolonged life span, this devastating disease remains invariably fatal by approximately 30 years of age. Considerable promising research is currently being conducted to treat DMD. These areas of research include viral (and other) delivery of mini or microdystrophin variants 1, 2 , stem/ progenitor cell transplantation 3 , exon skipping 4 and analog (eg. utrophin) upregulation 5 . While each of these approaches offer their own potential benefits, they are all hindered by one common limitation. Currently, the typical way to assess the impact of these approaches on muscle health is by invasive and painful muscle biopsies that may themselves contribute to further disease progression. In addition to the invasive nature of muscle biopsies, information gleaned from this tissue is limited to histological (H&E, Masson's trichrome stains), biochemical and molecular (western blotting, gene expression) analyses, that preclude any sort of longitudinal, functional assessment 6 . Thus, there is a critical need for ways to non-invasively assess disease progression and subsequent efficacy of therapeutic interventions 7 . The purpose of this review is to examine the potential use of various non-invasive imaging modalities for their use in monitoring disease progression and/or therapeutic outcome in DMD patients. Specifically, this review will highlight the benefits and limitations of magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT) as they may pertain to DMD research. While this review focuses on the use of these imaging modalities as they pertain to skeletal muscle specifically, their use for monitoring disease progression and therapeutic approaches in DMD-related cardiomyopathy is also promising and relevant to this discussion.
Magnetic resonance imaging
Magnetic resonance imaging (MRI) is an ideal imaging modality for visualising the anatomy of soft tissue within the body, thus offering many potential benefits for use in assessing muscle pathogenesis in both animal models of DMD, DMD patients and other patients suffering from a broad spectrum of myopathies [8] [9] [10] . To this end, MRI has been utilised to distinguish healthy versus dystrophic muscle in an mdx mouse model of DMD 11 . Specifically, proton transverse relaxation time-weighted images or T2 images, illustrated that degenerating muscle in mdx mouse hind limbs appeared more heterogeneous on an MR image compared to hind limb musculature of a wild-type mouse, which appears largely homogeneous; higher T2 values were attained in control muscles and these regions of interest appeared "lighter" than in the degenerating muscle in mdx mice. Histologically, the "dark" areas on a T2 map were found to correspond to areas of inflammation and macrophage infiltration in dystrophic muscle lesions. Additionally, some areas on a T2 map of dystrophic hind limbs exhibited an intense signal, indicating the presence of fatty infiltrate in the mdx mouse that was not present in healthy wild-type hind limb musculature 14 ; since albumin is known to accumulate in damaged myofibres due to sarcolemmal disruption 7, 15 , the authors used human serum albumin conjugated to a paramagnetic compound, gadolinium-DPTA, to assess its accumulation in dystrophic skeletal muscle. The results of this study indicated that this contrast agent did, in fact, accumulate in the degenerating myofibres of mdx mice but not in wild-type mice. Another recent study from 2010 reported the use of T2 mapping to examine the effect of corticosteroird treatment-the current gold standard therapy to inhibit/reduce inflammation-in DMD patients relative to both untreated and healthy patients 13 . While patient compliance is always a potential issue given the age of DMD patients, MR imaging may be safely repeated and confers no pain to the individual. Furthermore, MRI does not involve ionising radiation, making it an attractive tool for paediatric patient use. Taken together, these studies provide compelling evidence that MRI may be a valuable tool for providing information on global changes in muscle composition as disease progresses, with or without the use of therapeutic interventions.
Computed tomography X-ray computed tomography (CT) technology utilises computed-processed X-rays to produce a topographic image to produce a threedimensional image of the internal parts of an object. Dense tissues such as bones will attenuate an X-ray more than tissues that are composed largely of water or air. CT resolutions between tissue densities allow researchers to distinguish between tissues that vary by only 1% in their densities, making it an ideal tool to image fat and muscle tissue. Given these characteristics, CT has been in use since the 1980's, to monitor structural changes in dystrophic skeletal muscle, becoming a gold standard in assessing muscle degeneration [16] [17] [18] . Specifically, a 1990 study, described the use of CT as a tool for diagnosing DMD in patients given the density patterns on CT images of neck, shoulder, back, pelvis and leg muscles in DMD versus healthy patients 17 . A 1993 study by Liu et al., further used CT to measure the percent cross-sectional area (%CSA) of the hind limb muscles that were composed of muscle or fat. Out of the 71 patients tested, they were able to significantly correlate an increased %CSA of fat with decreased muscle function as DMD progressed. A recent 2013 study, however, highlights specific limitations to using CT to assess muscle involvement in DMD patients, which may explain the lack of routine clinical use. First, there are concerns with x-ray exposure to patients; repeated scans during a longitudinal study may be unsafe for paediatric patients. Additionally, the authors note that most CT methods are unable to distinguish between connective tissue and muscle, which makes it difficult to assess extent of fibrosis, another hallmark of DMD 19 . Dynamic contrast-enhanced CT (DCE-CT) may address this issue by providing measurements of perfusion in skeletal muscle. Since fibrotic tissue is for the most part, inert tissue, blood flow to those areas is limited and thus may be detected via DCE-CT. The use of a radiopaque contrast, such as iodine, is also ideally suited to monitor changes in muscle ischemia that are inherent to disease progression in DMD. Evidence in support of this comes from a study utilising weaklyaffected mdx mice and severelyaffected mdx:utrn-/-mice; here, authors correlated inflammation/ regeneration indicative of the early stages of DMD with a transient increase in muscle perfusion (blood flow and blood volume). As muscle pathology and fibrosis ensues in both dystrophic mouse models, a progressive decline in perfusion was observed 20 . This study provides rationale for using DCE-CT to monitor vascular-targeted therapies for treating DMD. Review of a radio-labelled substrate that will emit positrons after injection into the body. When a positron collides with a nearby electron, this coincidence event is captured by the PET scanner, allowing for localisation of the collision. Thus, depending on the radiolabelled substrate, positrons may be imaged in various types of cells and tissues. The most widely used substrate in patients today, mainly as a standard diagnostic imaging tool for cancer is fluorine 18 -labelled flurodeoxyglucose ( 18 F-FDG), a glucose analog. 18 F-FDG is taken up by cells that express the GLUT-1 glucose transporter, thus allowing for visualisation of metabolically active cells. While some studies have used PET-FDG for assessing muscular dystrophyrelated cardiomyopathy in patients 21 , it has yet to be assessed in significant studies of skeletal muscle metabolism in DMD patients. There is strong evidence, however, that PET-FDG will be a useful tool for monitoring degeneration in DMD patients since it is a direct indicator of skeletal muscle glucose metabolism [22] [23] [24] [25] [26] [27] . Areas of myofibre necrosis and subsequent fibrosis can be detected since fibrotic tissue is not metabolically active and thus should not accumulate 18 F-FDG 21 . As evidence of this, our group has also reported the use of 18 F-FDG-PET for monitoring skeletal muscle muscles. These findings were due to neck strain from being on a stretcher, gum chewing, laboured breathing, reading in the waiting room and nervous foot tapping, respectively, as indicated by technician notes. Although this study was performed on patients with suspected tumours, the findings of this study shed light on some potential sources of variability in 18 F-FDG uptake in skeletal muscle and therefore highlight the need for tight experimental controls and patient reporting.
Positron emission tomography

Hybrid scanners
Many of the current limitations to the use of MRI, CT and PET imaging of skeletal muscle in DMD may be addressed with the use of hybrid scanners. Hybrid PET/CT and PET/ MRI scanners provide the functional metabolic information offered by 18 F-FDG-PET while at the same time co-register those areas of uptake with anatomical data provided by CT or MRI 29, 30 . Since it is currently difficult to differentiate between connective and muscle tissue using MRI and CT, PET-FDG may provide further insight to metabolically active areas (muscle) versus metabolically inactive areas (fibrotic tissue). Table 1 outlines the advantages and disadvantages of the various imaging modalities to highlight their utility as standalone tools or as components of hybrid scanners. changes in dystrophic mice. In support of their parallel CT study, authors observed an early phase of inflammation and regeneration as evidenced by an increase in 18 F-FDG uptake in hind limb musculature. As muscle pathology and formation of fibrotic tissue were progressed, however, degeneration of myofibres was also accompanied by a progressive decrease in FDG uptake compared to wild-type controls 20 . While PET imaging may be a promising avenue for longitudinally assessing muscle degeneration and therapeutic interventions, there are a few limitations that must also be considered. A study by Yeung et al. in particular has highlighted some concerns with assessing 18 F-FDG uptake in skeletal muscle containing adipose tissue; this 2003 study used retrospective patient data to demonstrate that adipose tissue represents a source of false-positive 18 F-FDG uptake. This is a concern for imaging in DMD patients considering the fatty infiltrate that eventually dominates the degenerated muscle tissue 28 . Additionally, a 2006 study by Jackson et al. 23 , cited some other sources of variability in terms of measuring FDG uptake in skeletal muscle. Specifically, 12% of the 1,164 total patients scanned exhibited excessively elevated 18 F-FDG uptake in neck, masseter, chest wall, forearm and lower leg 
Discussion
The authors have referenced some of their own studies in this review. The protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. Animal care was in accordance with the institution guidelines.
The potential benefits that noninvasive imaging offers for both monitoring disease status and therapeutic outcome are numerous and may change our understanding of DMD progression and treatment in patients. From the perspective of a patient, non-invasive imaging would eliminate the need for painful muscle biopsies, which are the typical method of assessing muscle damage. Not only is this painful for the patient, but also the biopsy itself may incur further damage to already injured muscle. From a research standpoint, non-invasive imaging allows for more global analysis of what is happening in vivo, which is not offered by ex vivo histological analyses. DMD manifests as a very heterogeneous disease affecting certain muscle groups and even different areas within a muscle group differently 31, 32 . In fact, some muscle groups appear nearly unaffected in DMD. Depending on the tissue region selected for biopsy, this sample may drastically over or underestimate the true extent of damage in the patient. It has also been suggested that changes observed non-invasively may precede changes in physiological outcome, i.e. muscle contractile strength and endurance 20 , which is important when considering the timing of therapeutic intervention. It should be noted, however, that non-invasive imaging is not yet able to definitively diagnose DMD in patients [33] [34] [35] [36] . While new blood test techniques for detecting specific mutations in the dystrophin gene are being developed 37 , it would be advantageous to investigate the use of non-invasive imaging for diagnostic purposes as well.
Prior to the standard use of these imaging modalities for monitoring DMD, there are a few limitations that must be addressed. First and foremost, paediatric patient compliance will continue to be a hurdle for researchers, particularly for certain protocols that currently take up to 2 h to complete. Safety is another primary concern for the use of PET and CT in children since they both involve radiation. Radiation doses must be taken into account considering that children are at a higher risk of lifetime cancer mortalities attributable to radiation than adults 38 . Current research is attempting to implement dose reduction techniques using various software and hardware techniques that may reduce radiation dose by 2-3 fold 39 . Lastly, the noninvasive imaging techniques described in this review focus on their use for measuring muscle mass versus adipose tissue. As the disease manifests, however, fibrosis is perhaps as debilitating as muscle degeneration itself.
Conclusion
Current literature is unclear whether fibrosis in skeletal muscle may be noninvasively measured reliably in DMD patients since it is difficult to distinguish between fibrotic and muscle tissue using non-invasive imaging techniques. Thus, there exists a need to develop protocols to measure fibrosis using these and other imaging techniques. Regardless, the use of noninvasive imaging in standard clinical care is relatively new and is expected to increase over the coming years. Given the limitations of muscle biopsies and muscle strength tests, noninvasive imaging has the potential to shed new light on the efficacy of various therapeutic approaches and may enhance quality of life and increase life expectancy for DMD patients.
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